eligibility_summary
Eligibility: Adults (≥18) with histologically proven unresectable epithelioid MPM (stage I–IV), WHO PS 0–1, adequate marrow/organ function, HIV/HBV/HCV negative (or DNA/RNA negative per algorithm), nonpregnant, using contraception, able to comply/consent. Exclude: recent other cancer, active CNS/leptomeningeal disease, significant autoimmune or pneumonitis, major cardiac/surgical/infectious issues, prior MPM therapy, recent antibiotics/trials/live vaccines, transplants/ICIs, immunosuppression, severe allergy/atezo hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II single-arm trial in epithelioid malignant pleural mesothelioma combining: 1) Atezolizumab—anti–PD-L1 humanized IgG1 monoclonal antibody (checkpoint inhibitor) that blocks PD-L1 interaction with PD-1/B7.1 to restore antitumor T-cell function, 2) Autologous WT1 mRNA–loaded dendritic cell vaccine—cell therapy/cancer vaccine, dendritic cells present WT1 peptides to prime WT1-specific CD8+ and CD4+ T cells, 3) Standard cisplatin or carboplatin plus pemetrexed—cytotoxic chemotherapy (platinum DNA crosslinking, antifolate inhibition of thymidylate synthase and other folate enzymes). Targets/pathways: PD-1/PD-L1 checkpoint on tumor/myeloid cells, WT1 tumor antigen, dendritic cell–T-cell priming, proliferating tumor cells and potential chemotherapy-induced immunogenic cell death.